睿知中国疾病研究地图
候选清单0

正在招募胃癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial

ClinicalTrials.gov 上登记的一项胃癌开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07474324,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Pathological stage III gastric and gastroesophageal junction adenocarcinoma patients (according to the 8th edition of the American Joint Committee on Cancer [AJCC] staging system).

    入选标准第 5 条

    Possesses complete imaging and pathological clinical data;

    入选标准第 11 条

  3. Primary stage III gastric or gastroesophageal-junction adenocarcinoma not histologically or cytologically confirmed;

    排除标准第 1 条

  4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.

    入选标准第 7 条

  5. Other malignancies within 5 years before screening, except adequately treated cancers considered cured (e.g., thyroid cancer, cervical carcinoma in situ, basal/squamous-cell skin cancer, or ductal carcinoma in situ of the breast treated with curative surgery);

    排除标准第 9 条

  6. Lactating women;

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07474324,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Aged between 18 and 75 years.
  2. Have undergone radical resection with D2 or wider lymph node dissection and achieved R0 resection status.
  3. No prior systemic anti-tumor treatment (i.e., neoadjuvant therapy) before surgery.
  4. Histopathologically confirmed gastric adenocarcinoma.
  5. Pathological stage III gastric and gastroesophageal junction adenocarcinoma patients (according to the 8th edition of the American Joint Committee on Cancer [AJCC] staging system).
  6. HER2 moderate-to-high expression (IHC 3+ or 2+).
  7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  8. Expected survival time ≥ 3 months.
  9. Able to understand the study protocol, voluntarily participate in the study, and provide written informed consent;
  10. Good compliance and able to cooperate with the treatment regimen specified in this study;
  11. Possesses complete imaging and pathological clinical data;
  12. Adequate organ and bone-marrow function.

排除标准:Exclusion Criteria:

  1. Primary stage III gastric or gastroesophageal-junction adenocarcinoma not histologically or cytologically confirmed;
  2. Unable to receive disitamab vedotin or SOX chemotherapy;
  3. Unable to comply with the required follow-up schedule;
  4. Unable to accept the treatment regimen specified in this protocol;
  5. Unable or unwilling to undergo mandated response assessments (e.g., CT imaging);
  6. Active autoimmune disease;
  7. History of psychoactive-substance abuse that cannot be discontinued, or any severe/uncontrolled psychiatric disorder, or any severe/uncontrolled systemic disease;
  8. Any concomitant condition that, in the investigator's opinion, poses significant risk to the subject or could compromise study completion;
  9. Other malignancies within 5 years before screening, except adequately treated cancers considered cured (e.g., thyroid cancer, cervical carcinoma in situ, basal/squamous-cell skin cancer, or ductal carcinoma in situ of the breast treated with curative surgery);
  10. Lactating women;
  11. Prior neoadjuvant therapy or intra-operative intraperitoneal chemotherapy.

引自 ClinicalTrials.gov, NCT07474324, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07474324,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07474324